Curis, Inc. (CRIS) News
Filter CRIS News Items
CRIS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CRIS News From Around the Web
Below are the latest news stories about CURIS INC that investors may wish to consider to help them evaluate CRIS as an investment opportunity.
Curis Announces Additional Data from TakeAim Leukemia StudyCuris, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. |
Curis Third Quarter 2024 Earnings: Beats ExpectationsCuris ( NASDAQ:CRIS ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.93m (up 3.5% from 3Q 2023). Net... |
Q3 2024 Curis Inc Earnings CallQ3 2024 Curis Inc Earnings Call |
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...Curis Inc (CRIS) reports reduced net loss and promising clinical trial results, while addressing financial and regulatory hurdles. |
Curis (CRIS) Reports Q3 Loss, Tops Revenue EstimatesCuris (CRIS) delivered earnings and revenue surprises of 9.57% and 3.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Curis: Q3 Earnings SnapshotLEXINGTON, Mass. AP) — Curis Inc. CRIS) on Thursday reported a loss of $10.1 million in its third quarter. |
Curis Provides Third Quarter 2024 Business UpdateCuris, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended September 30, 2024. |
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. |
Curis price target lowered to $20 from $26 at H.C. WainwrightH.C. Wainwright lowered the firm’s price target on Curis (CRIS) to $20 from $26 and keeps a Buy rating on the shares. The firm cites dilution from this week’s registered direct offering for the target cut. Additional data from the TakeAim lymphoma study is expected in December and in Q1 of 2025, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts |
Curis Announces $12.1 Million Registered Direct and Concurrent Private PlacementCuris, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 2,398,414 shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Curis also agreed to issue to the investors in the reg |